Radioimmunotherapy of leukemia. Adv Pharmacol. 2004;51:185-208. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment ... Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. It is a ... Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):297-304. Dadachova E, Nosanchuk JD, Shi L, ... A set of radioimmunotherapy drugs that rely upon an alpha-emitting isotope (e.g., bismuth-213 or, preferably, actinium-225), ...

... and the results indicate that radioimmunotherapy is more effective than either radiotherapy or immunotherapy alone. ... Dynamics of an Antitumour Model with Pulsed Radioimmunotherapy. Gang Wang. ,1Ming Yi. ,2and Sanyi Tang. 3 ... Numerous studies have shown that radioimmunotherapy is more effective for inhibiting tumour growth than radiotherapy [4, 20]. ... are determined through numerical simulations, and the results indicate that radioimmunotherapy is more effective than either ...

... named in this special issue radioimmunotherapy. However, one has always to keep in mind that many challenges do still exist ... Editorial: Radioimmunotherapy-Translational Opportunities and Challenges. Udo S. Gaipl1* Gabriele Multhoff2 A. Graham Pockley3 ... Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. Strahlenther Onkol. (2018) 194:509- ... This again high lights the huge translational opportunities of radioimmunotherapies (Palata et al.). Besides cytokines, active ...

Health Canada has approved a new treatment that could offer hope for those who suffer from what is considered an incurable form of non-Hodgkins lymphoma (NHL) and who have failed on, or relapsed following, other treatments. Health Canada approved Bexxar(TM) (tositumomab and iodine I 131 tositumomab) therapy for the treatment of patients with CD20 positive relapsed or

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol. 1997;65:94-101. ... Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab. Ruby Meredith, Julien Torgue ... Intracavitary radioimmunotherapy to treat solid tumors. Cancer Biother Radiopharm. 2008;23:92-107. ... A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy. Clin Cancer Res. 1999;5:3044s-3047s. ...

Radioimmunotherapy (RIT) is a treatment for cancer which combines radiation and immune therapy using monoclonal antibodies. RIT ... A Model-Based Approach for the Optimization of Radioimmunotherapy through Antibody Design and Radionuclide Selection, Aiden A. ... A Model-Based Approach for the Optimization of Radioimmunotherapy through Antibody Design and Radionuclide Selection ... A Model-Based Approach for the Optimization of Radioimmunotherapy through Antibody Design and Radionuclide Selection ...

... ... Intraperitoneal radioimmunotherapy with an 211At-labelled specific antibody is an effective treatment of human ovarian cancer ... Thus there is a great need for consolidating therapy.Radioimmunotherapy (RIT), i.e. treatment with specific monoclonal ...

Targeted Radioimmunotherapy. Follicular lymphoma is inherently radiosensitive, so the development of targeted ... Other first-line treatment options include rituximab, alone or in combination with other agents, and radioimmunotherapy ... Combination treatment with involved-field radiation therapy (IFRT) and chemotherapy (see below) and/or radioimmunotherapy is ... What is the role of targeted radioimmunotherapy in the treatment of follicular lymphoma? ...

... Grana, Chiara Maria. Primo. ;Paganelli, Giovanni. Ultimo. 2013. Abstract. Gliomas and ... trials in brain tumors have almost exclusively exploited the potential of radioimmunotherapy (RIT) by employing a radiolabeled ... trials in brain tumors have almost exclusively exploited the potential of radioimmunotherapy (RIT) by employing a radiolabeled ...

Targeted Radioimmunotherapy. Follicular lymphoma is inherently radiosensitive, so the development of targeted ... Other first-line treatment options include rituximab, alone or in combination with other agents, and radioimmunotherapy ... Combination treatment with involved-field radiation therapy (IFRT) and chemotherapy (see below) and/or radioimmunotherapy is ... What is the role of targeted radioimmunotherapy in the treatment of follicular lymphoma? ...

Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on ... Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on ... Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on ...

We aim to expedite the clinical translation of the developed radioimmunotherapy approaches by investigating the early ... Methods: Mice bearing BxPC3 tumor xenografts were treated with α- and β-particle pretargeted radioimmunotherapy (PRIT), ... DNA damage, PET, Radioimmunotherapy, pancreatic cancer, γH2AX, Alpha Particles, Animals, Antigens, Tumor-Associated, ... We aim to expedite the clinical translation of the developed radioimmunotherapy approaches by investigating the early ...

Radioimmunotherapy with alpha-emitting nuclides journal, September 1998 * McDevitt, Michael R.; Sgouros, George; Finn, Ronald D ...

Radioimmunotherapy cures human non-Hodgkin lymphoma in animal model A new nuclear medicine therapy can cure human non-Hodgkin ...

Radioimmunotherapy with an 211At-labeled anti-tissue factor antibody protected by sodium ascorbate. In: Cancer Science. 2021 ; ... Radioimmunotherapy with an 211At-labeled anti-tissue factor antibody protected by sodium ascorbate. Cancer Science. 2021 May; ... Radioimmunotherapy with an 211At-labeled anti-tissue factor antibody protected by sodium ascorbate. / Takashima, Hiroki; Koga, ... Radioimmunotherapy with an 211At-labeled anti-tissue factor antibody protected by sodium ascorbate. ...

Integrated Treatment Planning System To Calculate Three Dimensional Absorbed Dose For Radio-Immunotherapy. Title. Integrated ... Treatment Planning System To Calculate Three Dimensional Absorbed Dose For Radio-Immunotherapy. Publication Type. Conference ...

Combination radio-immunotherapy against 9464D-GD2 neuroblastoma tumors: some small tumors are cured, but not larger tumors. ... We recently described an effective combination radio-immunotherapy treatment regimen (combination adaptive-innate immunotherapy ... A combination radio-immunotherapy regimen (external beam radiotherapy, hu14.18-IL2 immunocytokine, CpG, anti-CD40, and anti- ... We previously described a combination radio-immunotherapy regimen (CAIR) that is effective in 9464D-GD2 tumors (figure 1A).4 We ...

Radioimmunotherapy. Sofia Frost, Tom Bäck, Nicolas Chouin, Holger Jensen, Ragnar Hultborn, Lars Jacobsson, Sture Lindegren ... Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice. Jörgen Elgqvist, Håkan Andersson, Holger Jensen, ... Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Jörgen Elgqvist, Håkan Andersson, Elin ... Intraperitoneal alpha-radioimmunotherapy of ovarian cancer - pharmacokinetics and dosimetry of 211At-MX35 F(ab)2 in a phase I ...

Radioimmunotherapy (RIT) (American College of Radiology; Radiological Society of North America) Also in Spanish ...

Stapled liposomes enhance cross-priming of radio-immunotherapy. Adv. Mater. (Deerfield Beach, Fla.) 34, e2107161 (2022). ... FLT3L release by natural killer cells enhances response to radioimmunotherapy in preclinical models of HNSCC. Clin. Cancer Res. ... Metabolic homeostasis-regulated nanoparticles for antibody-independent cancer radio-immunotherapy. Adv. Mater. 34, e2207343 ( ... Metal-cyclic dinucleotide nanomodulator-stimulated STING signaling for strengthened radioimmunotherapy of large tumor. Small ( ...

The objective of this study was to evaluate the potential of targeting CD138 by immuno-PET imaging and radioimmunotherapy (RIT ... From: Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A ...

0267: Potential of Bi-213-Pankomab for Radioimmuno- Therapy: in Vitro Cytotoxicity and Biodistribu- Tion in Mice with ... 0267: Potential of Bi-213-Pankomab for Radioimmuno- Therapy: in Vitro Cytotoxicity and Biodistribu- Tion in Mice with ...

Radioimmunotherapy studies in p53-positive HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in ... Radioimmunotherapy studies in p53-positive HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in ... Radioimmunotherapy studies in p53-positive HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in ... Radioimmunotherapy studies in p53-positive HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in ...

Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in ... Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in ... MeSH]: Radioimmunotherapy. [DDC subject group]: DDC 610 / Medicine & health. License CC BY-NC 4.0 International. https:// ... of the entire treatment scheme consisting of induction chemoimmunotherapy followed by chemotherapy-free radioimmunotherapy (RIT ...

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 ... Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 ... Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 ... Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma : Long-term follow-up of a phase 1/2 ...

... with improved efficacy at the higher radioimmunotherapy doses. Conclusions: Fractionated radioimmunotherapy with 90Y-hPAM4 and ... Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic ... 2012). Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced ... 2012). Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced ...

Chief of Radioimmunotherapy, Radiation Oncology. Professor of Radiation Oncology. City of Hope ...

Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing ...

New Radioimmunotherapy Cures Epithelial Ovarian Cancer in a Preclinical Study. Sep 15, 2023. AI Identifies Improperly ...

Radioimmunotherapy such as zevalin or Bexxar (tositumomab) can have multiple side effects: infusion reactions such as fevers, ...